Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients

NCT: NCT07525310 · NOT_YET_RECRUITING

NCT IDNCT07525310
StatusNOT_YET_RECRUITING
Start Date2026-05-01
Completion2027-11-30

Brief Summary

This double-blind, randomized, sham-controlled clinical trial aims to evaluate the effects of vascular photobiomodulation on blood pressure and vascular function in hypertensive patients treated with losartan. A total of 80 patients using losartan (100 mg/day for at least two months) will be recruited and followed for 4 weeks. Participants will be randomly allocated to either an active photobiomodulation group or a sham control group.

Frequently Asked Questions

What is Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients?

Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients is a clinical trial registered under NCT07525310. Current status: NOT_YET_RECRUITING.

What is the status of NCT07525310?

The current status of NCT07525310 (Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients) is: NOT_YET_RECRUITING.

When did Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients start?

Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑